N1-(1-苄基-4-哌啶基)苯-1,2-二胺 | 57718-47-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 中文名称: N1-(1-苄基-4-哌啶基)苯-1,2-二胺
• 英文名称: N-(1-benzyl-piperidin-4-yl)-benzene-1,2-diamine
• 英文别名: N¹-(1-benzylpiperidin-4-yl)benzene-1,2-diamine；N-[1-(phenylmethyl)piperidin-4-yl]benzene-1,2-diamine；1-N-(1-Benzyl-piperidin-4-yl)-benzene-1,2-diamine；N1-(1-benzylpiperidin-4-yl)benzene-1,2-diamine；2-N-(1-benzylpiperidin-4-yl)benzene-1,2-diamine
• CAS: 57718-47-5
• 化学式: C₁₈H₂₃N₃
• 分子量: 281.401
• InChiKey: MHXACMFKKGZLNW-UHFFFAOYSA-N

物化性质

• 熔点：
  111 °C
• 沸点：
  447.1±45.0 °C(Predicted)
• 密度：
  1.157±0.06 g/cm3(Predicted)
• 溶解度：
  溶于DCM、DMSO。甲醇

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  21
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  41.3
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 危险品标志：
  Xi
• 海关编码：
  2933399090

SDS

Name:	N1-(1-Benzyl-4-piperidyl)benzene-1 2-diamine tech Material Safety Data Sheet
Synonym:
CAS:	57718-47-5

Section 1 - Chemical Product MSDS Name:N1-(1-Benzyl-4-piperidyl)benzene-1 2-diamine tech Material Safety Data Sheet
Synonym:

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
57718-47-5	N1-(1-Benzyl-4-piperidyl)benzene-1,2-d		260-916-3

Hazard Symbols: C
Risk Phrases: 34

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Causes burns.
Potential Health Effects
Eye:
Causes eye burns.
Skin:
Causes skin burns.
Ingestion:
Causes gastrointestinal tract burns.
Inhalation:
Causes chemical burns to the respiratory tract.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Immediately flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid immediately.
Skin:
Get medical aid immediately. Immediately flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Do not induce vomiting. Get medical aid immediately.
Inhalation:
Get medical aid immediately. Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use foam, dry chemical, or carbon dioxide.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

---

Section 7 - HANDLING and STORAGE
Handling:
Do not breathe dust, vapor, mist, or gas. Do not get in eyes, on skin, or on clothing. Use only in a chemical fume hood.
Storage:
Store in a cool, dry place. Store in a tightly closed container.
Corrosives area.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 57718-47-5: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: purple
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 110 - 115 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature: Not available.
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C18H23N3
Molecular Weight: 281

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Strong oxidizing agents.
Hazardous Decomposition Products:
Hydrogen cyanide, nitrogen oxides, carbon monoxide, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 57718-47-5 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
N1-(1-Benzyl-4-piperidyl)benzene-1,2-diamine - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Shipping Name: AMINES, SOLID, CORROSIVE, N.O.S.*
Hazard Class: 8
UN Number: 3259
Packing Group: III
IMO
Shipping Name: AMINES, SOLID, CORROSIVE, N.O.S.
Hazard Class: 8
UN Number: 3259
Packing Group: III
RID/ADR
Shipping Name: AMINES, SOLID, CORROSIVE, N.O.S.
Hazard Class: 8
UN Number: 3259
Packing group: III

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: C
Risk Phrases:
R 34 Causes burns.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 36/37/39 Wear suitable protective clothing, gloves
and eye/face protection.
S 45 In case of accident or if you feel unwell, seek
medical advice immediately (show the label where
possible).
WGK (Water Danger/Protection)
CAS# 57718-47-5: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 57718-47-5 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 57718-47-5 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  N1-(1-苄基-4-哌啶基)苯-1,2-二胺 在 palladium on activated charcoal 盐酸 、 甲酸铵 作用下， 以 甲醇 为溶剂， 生成 1-(哌啶-4-基)-1H-苯并[d]咪唑
  参考文献：
  名称：

  Potent 1,3,4-trisubstituted pyrrolidine CCR5 receptor antagonists: effects of fused heterocycles on antiviral activity and pharmacokinetic properties

  摘要：

  A series of 1,3,4-trisubstituted pyrrolidine CCR5 receptor antagonists containing a variety of fused heterocycles at the 4-position of the piperidine side chain has been discovered, which are orally bioavailable with potent anti-HIV activity. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.02.030
• 作为产物：
  描述：

  4-氨基-1-苄基哌啶 在 5 % platinum on carbon 、 氢气 、 potassium carbonate 作用下， 以 四氢呋喃 、 水 、 N,N-二甲基甲酰胺 为溶剂， 20.0~100.0 ℃ 、303.99 kPa 条件下， 反应 4.5h， 生成 N1-(1-苄基-4-哌啶基)苯-1,2-二胺
  参考文献：
  名称：

  IDO/TDO 이중 저해용 화합물 및 이를 포함하는 약학적 조성물

  摘要：

  本发明的化学式 (I) 所表示的三元环式衍生物，或其立体异构体，或药学上可接受的盐，具有对 IDO（吲哚胺-2,3-双加氧酶）和 TDO（色氨酸-2,3-双加氧酶）的双重抑制效果。包含这些物质的药物组合物可用于预防或治疗由 IDO 或 TDO 介导的疾病或障碍。

  公开号：

  KR20230155834A

文献信息

• N-(3-(4-substituted-1-piperidinyl)-1-phenylpropyl) substituted sulfonamides as NK-3 receptor antagonists
  申请人：——

  公开号：US20040002504A1

  公开（公告）日：2004-01-01

  The present invention provides a method of treatment of a subject suffering from a disease, such as schizophrenia, for which the administration of an NK-3 antagonist is indicated which comprises administering to that subject a therapeutically effective amount of a compound of formula I: 1 wherein, generally, Q is 2 R 1 is benzyl, phenyl, thiophene or imidazolyl optionally substituted with C 1-4 alkyl or halogen, such as methyl, fluorine or bromine; R 2 is hydrogen or C 1-4 alkyl such as methyl; R 3 is phenyl; R 4 is hydrogen; R 5 is hydrogen or C 1-6 alkylcarbonyl such as methylcarbonyl; X is —SO 2 — or —C(O)N(R 2 )SO 2 — where R 2 is preferably hydrogen; Y is a bond, CH 2 or Z 1 where Z 1 is —N(R f )— in which R f is C 1-6 alkylcarbonyl such as ethylcarbonyl; and R 6 is phenyl, pyrazolyl, pyridyl, pyrimidinyl or benzimidazolonyl optionally substituted with one or two groups chosen from C 1-6 alkyl and benzyl, such as methyl, ethyl and benzyl; or a pharmaceutically acceptable salt thereof.

  本发明提供了一种治疗患有疾病（如精神分裂症）的受试者的方法，其中该疾病的治疗需要使用NK-3拮抗剂，包括向该受试者施用化合物I的治疗有效量： 1 其中，通常情况下， Q是 2 R 1 是苄基、苯基、噻吩或咪唑基，可选择地用C 1-4 烷基或卤素（如甲基、氟或溴）取代； R 2 是氢或C 1-4 烷基，如甲基； R 3 是苯基； R 4 是氢； R 5 是氢或C 1-6 烷基羰基，如甲基羰基； X是—SO 2 —或—C(O)N(R 2 )SO 2 —，其中R 2 最好是氢； Y是键、CH 2 或Z 1 ，其中Z 1 是—N(R f )—，其中R f 是C 1-6 烷基羰基，如乙基羰基；以及 R 6 是苯基、吡唑基、吡啶基、嘧啶基或苯并咪唑基，可选择地用来自C 1-6 烷基和苄基的一个或两个基团取代，如甲基、乙基和苄基； 或其药学上可接受的盐。
• Pyrrolidine modulators of chemokine receptor activity
  申请人：Merck & Co., Inc.

  公开号：US06248755B1

  公开（公告）日：2001-06-19

  The present invention is directed to pyrrolidine compounds of the formula I: (wherein R1, R2, R3, R4, R5, R6, R14 and n are defined herein) which are useful as modulators of chemokine receptor activity. In particular, these compounds are useful as modulators of the chemokine receptors CCR-5 and/or CCR-3.

  本发明涉及式I的吡咯烷化合物： （其中R1，R2，R3，R4，R5，R6，R14和n的定义如本文中）这些化合物可用作调节化学趋化因子受体活性的调节剂。特别是，这些化合物可用作调节CCR-5和/或CCR-3的化学趋化因子受体的调节剂。
• Synthesis of benzimidazoles from 1,1-dibromoethenes
  作者：Wang Shen、Todd Kohn、Zice Fu、XianYun Jiao、Sujen Lai、Michael Schmitt

  DOI：10.1016/j.tetlet.2008.10.030

  日期：2008.12

  substituted benzimidazoles from 1,1-dibromoethenes and o-diaminobenzenes is described. The reaction employs DABCO as the base and NMP as the solvent. A variety of substitutions on both 2-aryl-1,1-dibromoethenes and o-diaminobenzenes are tolerated. This new procedure is carried out under mildly basic conditions, which may provide a complementary route to the existing preparations of benzimidazoles.

  描述了一种温和而有效的方法，用于由1,1-二溴乙烯和邻二氨基苯制备取代的苯并咪唑。该反应以DABCO为碱，NMP为溶剂。在2-芳基-1，1-二溴乙烯和邻-二氨基苯上的各种取代是可容忍的。该新方法在温和的碱性条件下进行，可能为现有苯并咪唑制剂提供补充途径。
• Derivatives of 3-hydroxy-pyrrole-2,4-dicarboxylic acid and uses thereof
  申请人：Cholody M. Wieslaw

  公开号：US20050026991A1

  公开（公告）日：2005-02-03

  Chemical agents of the general formula (I) and (II), such as derivatives of 3-hydroxy-pyrrole containing hydroxamic acid, and including salts thereof, that modulate levels of gene expression in cellular systems, including cancer cells, are disclosed, along with methods for preparing such agents, as well as pharmaceutical compositions containing such agents as active ingredients and methods of using these as therapeutic agents.

  揭示了一般式（I）和（II）的化学试剂，例如含有羟肟酸的3-羟基吡咯衍生物及其盐，这些试剂可以调节细胞系统中的基因表达水平，包括癌细胞。同时还公开了制备这些试剂的方法，以及含有这些试剂作为活性成分的药物组合物，以及使用这些试剂作为治疗剂的方法。
• [EN] SUBSTITUTED BENZIMIDAZOLES AS NOCICEPTIN RECEPTOR MODULATORS<br/>[FR] BENZIMIDAZOLES SUBSTITUÉS EN TANT QUE MODULATEURS D'UN RÉCEPTEUR DE NOCICEPTINE
  申请人：SCRIPPS RESEARCH INST

  公开号：WO2014153529A1

  公开（公告）日：2014-09-25

  The invention provides modulators of the nociceptin receptor (NOP), including both agonists and antagonists. A compound of the invention can be a selective modulator of NOP with respect to the μ- and κ- opioid receptors (MOP and KOP), thus providing a therapeutic method for the treatment of conditions wherein selective NOP modulation is medically indicated and MOP or KOP modulation may be less desirable. A compound of the invention can be a NOP full agonist, partial agonist, inverse agonist, positive or negative allosteric modulator, or a functionally biased agonist. A compound of the invention can be used for the treatment of an anxiety state, post-traumatic stress disorder, addictive disorders (including overuse of alcohol, tobacco, and drugs of abuse such as cocaine, amphetamines, and opitates), misregulated food intake and/or energy expenditure, cough, sleep disorders, migraine, pain, depression, or neurodegenerative disorders such as Parkinsons disease or Alzheimers disease.

  该发明提供了辅料受体（NOP）的调节剂，包括激动剂和拮抗剂。该发明的化合物可以是NOP的选择性调节剂，相对于μ-和κ-阿片受体（MOP和KOP），因此提供了一种治疗方法，用于治疗需要选择性NOP调节而MOP或KOP调节可能不太理想的疾病。该发明的化合物可以是NOP的全激动剂、部分激动剂、逆激动剂、正或负变构调节剂，或功能性偏向激动剂。该发明的化合物可用于治疗焦虑状态、创伤后应激障碍、成瘾性障碍（包括滥用酒精、烟草和可卡因、安非他明和阿片类等药物）、食物摄入和/或能量消耗失调、咳嗽、睡眠障碍、偏头痛、疼痛、抑郁症，或帕金森病或阿尔茨海默病等神经退行性疾病的治疗。